Developer docs
API playgroundTry for free, no card

Search company profiles

HekaBio

Full company profile

uuid0000xc6

Namestring
HekaBio
Legal namestring
HekaBio K.K.
Websiteurl
heka.bio
Company typeenum
Private
Founded yearint
2016
Descriptiontext

HekaBio K.K. is a privately held Tokyo-based healthcare platform founded in 2016 that operates an asset-light in-licensing, development, and commercialization model for world-leading biopharma and MedTech assets in Japan and the broader APAC region. The company addresses the well-documented drug and device lag between Japan and Western markets by acquiring rights to de-risked, early-stage assets from overseas innovators and shepherding them through PMDA regulatory pathways, clinical trials, reimbursement negotiations, and commercial launch. HekaBio's portfolio spans approximately 50 programs across oncology, autoimmune and inflammatory diseases, CNS and neurodegenerative disorders, ophthalmology, and regenerative medicine, with its flagship Alpha DaRT alpha-particle radiation therapy system having received Shonin marketing approval from Japan's Ministry of Health, Labour and Welfare in February 2025 for unresectable locally advanced or recurrent head and neck cancer, marking the first regulatory approval for the platform outside Israel.

The company's revenue model is based on licensing milestones and royalties from commercialization of in-licensed products, supplemented by strategic investments from corporate partners. HekaBio holds Japanese regulatory permits for Class I medical device manufacturing/sales and highly managed medical device sales/rental, enabling it to directly commercialize approved products. Its go-to-market relies on channel partnerships, most notably with Alfresa Holdings (Japan's largest pharmaceutical wholesaler at 2.9 trillion yen consolidated sales) for nationwide distribution, and direct relationships with leading clinical centers including the National Cancer Center Hospital, Tohoku University Hospital, and the Institute of Science Tokyo for trial execution and clinical adoption. Core products include the Alpha DaRT System (intratumoral radium-224 alpha-particle therapy), Precision-GI endoscopic biopsy device (from Limaca Medical), BetaCurve ophthalmic radiation therapy (from SalutarisMD), troculeucel NK cell therapy (from NKGen Biotech), SP163M neuropathy peptide (from Serpin Pharma), and the K-EXP biomarker platform (from KIFFIK Biomedical).

HekaBio is led by co-founders Rob Claar (CEO) and Ben Pratt (COO), who leverage prior experience from Junicon K.K. (healthcare market research) and Vorpal Technologies K.K. (pharmaceutical and medical device CRO). The advisory and board bench includes former Japan presidents of AbbVie, Merck KGaA, and Pfizer, former Salesforce/Yext CFO Steven Cakebread, and international M&A attorney Stephen Chelberg of Squire Patton Boggs. The company is currently transitioning from a development-stage platform to commercial-stage operations following Alpha DaRT approval.

Short descriptiontext

HekaBio is a Tokyo-based asset-light biopharma and MedTech platform that in-licenses early, de-risked healthcare innovations from overseas and commercializes them in Japan and APAC. It serves Japanese patients with cancer, autoimmune, CNS, and ophthalmic diseases, and overseas innovators seeking Japan/APAC market access.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersTokyo, Japan
HQ citystring
Tokyo
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharma licensing platform, medical device commercialization, pharmaceutical market access, radiation therapy oncology, regulatory affairs Japan
Industry4 codes
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
  • Scientific Research and Development Services5417
SIC code3 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceutical and MedTech Licensing & Commercialization
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Commercialization
TypeLicensing Royalties
Description

HekaBio generates revenue through licensing agreements with overseas biotech/MedTech companies for Japanese market rights. They earn milestone payments during development phases and royalties upon commercialization. They also receive strategic investments from partners.

heka.bio
2Strategic Investments
TypeLicensing Royalties
Description

The company raises capital through private funding rounds from corporate investors and financial partners to fund portfolio expansion and operations.

heka.bio
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

HekaBio K.K. is a biopharma and MedTech in-licensing and commercialization platform that brings world-leading healthcare innovations to Japan and the Asia-Pacific region. The company identifies, de-risks, clinically develops, secures regulatory approval (PMDA), and commercially launches overseas assets across oncology (including the approved Alpha DaRT alpha-radiation therapy), ophthalmology (BetaCurve), regenerative medicine (troculeucel NK cell therapy), and diagnostics (Precision-GI biopsy device), with revenue generated primarily through licensing milestones and royalties from partners such as Alpha Tau Medical, Limaca Medical, SalutarisMD, NKGen Biotech, and Serpin Pharma.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Portfolio of nearly 50 programs under management
+1 more record
Product overview1 text field

HekaBio is an asset-light emerging commercial-stage biopharma and MedTech platform that in-licenses, develops, and commercializes world-leading healthcare innovations in Japan and the Asia-Pacific region. The company operates as a portfolio of partnered products rather than a single unified product. Its core offerings include the Alpha DaRT System (alpha-particle radiation cancer therapy) as its primary commercial product, supplemented by partnership-based products including Precision-GI (endoscopic biopsy device), K-EXP Platform (interstitial fluid diagnostics), BetaCurve (ophthalmic radiation therapy), troculeucel (NK cell therapy), SP163M (neuropathy treatment), and the Terrapeutics drug discovery platform. HekaBio focuses on oncology, CNS/neurodegenerative diseases, and autoimmune/inflammatory disorders, providing clinical development, regulatory navigation, and commercialization support through its network of pharma, MedTech, and hospital partners.

Product and service6 records
1Alpha DaRT System
CategoryRadiation therapy oncology device
Description

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is an alpha-particle cancer treatment that delivers intratumoral radium-224 sources to destroy solid tumors while sparing healthy tissue. HekaBio's primary commercial product, licensed from Alpha Tau Medical, received Shonin marketing approval in Japan for unresectable locally advanced or recurrent head and neck cancer.

2Precision-GI Endoscopic Biopsy Device
CategoryEndoscopic diagnostic medical device
Description

Precision-GI is an automated motorized endoscopic ultrasound (EUS) biopsy device developed by Limaca Medical for improved tissue sampling in gastrointestinal cancer diagnosis, particularly pancreatic cancer. HekaBio holds Japanese commercialization rights and is preparing the device for the Japan market following its FDA 510(k) clearance.

3BetaCurve
CategoryOphthalmic radiation therapy device
Description

BetaCurve is an ophthalmic device developed by SalutarisMD that incorporates Strontium-90 for controlled delivery of episcleral radiation to treat Polypoidal Choroidal Vasculopathy (PCV), a subset of neovascular Age-related Macular Degeneration with high prevalence in Asia. HekaBio holds Japan commercialization rights.

4troculeucel (Autologous NK Cell Therapy)
CategoryRegenerative cell therapy
Description

Troculeucel is an autologous NK cell therapy developed by NKGen Biotech intended for treating neurodegenerative diseases including Alzheimer's disease and Parkinson's disease. HekaBio is partnering to bring troculeucel to Japan under Japan's regenerative medicine regulatory framework.

5K-EXP Interstitial Fluid Molecular Measurement Platform
CategoryIn-vitro diagnostic / biomarker detection platform
Description

The K-EXP platform, developed by KIFFIK Biomedical, performs interstitial fluid (ISF) molecular measurement enabling biomarker detection across oncology, cardiology, neurology, and dermatology. HekaBio is leading the platform's expansion across Japan and the Asia-Pacific region.

6SP163M Peptide Drug
CategoryPeptide therapeutic / supportive care drug
Description

SP163M is a peptide drug developed by Serpin Pharma for prevention of chemotherapy-induced peripheral neuropathy (CIPN). It protects nerves from neurotoxic chemotherapy drugs, facilitates nerve repair, and alleviates pain. HekaBio holds the commercialization lead in Japan, Korea, Taiwan, Australia, ASEAN, the Middle East, and North Africa.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-24
Description

Strategic alliance to expand K-EXP interstitial fluid (ISF) molecular measurement platform across Japan and APAC. HekaBio will support regulatory strategy in Japan, serve as local strategic advisor, and assist in establishing clinical and commercial partnerships in Japan and Korea. Platform enables biomarker detection across oncology, cardiology, neurology, and dermatology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-24
Description

Long-standing partnership to develop and commercialize Alpha DaRT (Diffusing Alpha Radiation Therapy) for solid tumors in Japan. Alpha Tau developed the technology and obtained Japanese regulatory approval (Shonin) through HekaBio's support. HekaBio preparing commercial launch and post-marketing surveillance. Japan is first country outside Israel to approve this innovative alpha-particle cancer therapy.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-10-02
Description

Strategic partnership to expand generational health access in Japan. Partnership focuses on delivering innovative healthcare solutions across generations through global investment platform capabilities.

4Indonesia Inovasi Sehat
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

Strategic agreement to promote advanced medical technology adoption in Indonesia. Partnership aims to improve patient outcomes by delivering innovative solutions to healthcare providers, reflecting shared mission across borders.

heka.bio
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-21
Description

Strategic partnership to bring novel autologous NK cell therapy (troculeucel) to Japan for neurodegenerative diseases including Alzheimer's and Parkinson's. Partnership aims to accelerate regulatory, manufacturing, and commercialization processes under Japan's regenerative medicine regulations.

6Alfresa Holdings Corporation
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-06-16
Description

Strategic commercialization partnership with Japan's #1 pharmaceutical wholesale company (2.9 trillion yen consolidated sales). Alfresa will support distribution and commercialization of innovative pharmaceutical products. HekaBio also received capital investment from Alfresa as part of this partnership to accelerate market entry.

heka.bio
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-07-09
Description

Partnership for SP163M peptide drug development to prevent chemotherapy-induced peripheral neuropathy (CIPN). HekaBio will lead commercialization in Japan, Korea, Taiwan, Australia, ASEAN, Middle East, and North Africa. Includes strategic investment in Serpin Pharma.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-06-19
Description

Partnership to introduce Terrapeutics' innovative drug discovery platform leveraging soil bacteria-derived molecules to Japanese pharma. HekaBio CEO Rob Claar joins Terrapeutics' Advisory Board. Platform enables rapid identification of natural inhibitors for challenging drug targets.

9Limaca Medical Ltd.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-05-17
Description

Partnership for Precision-GI endoscopic biopsy device for Japanese market. HekaBio supporting regulatory approval from PMDA, sales preparation, physician training, and domestic logistics. Device received FDA 510(k) clearance and CMS TPT payment approval in US, with HekaBio pursuing Japanese commercialization.

heka.bio
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-07-09
Description

Licensing and commercialization agreement for BetaCurve device - Sr90 beta radiation delivery system for Polypoidal Choroidal Vasculopathy (PCV) treatment, a subset of wet age-related macular degeneration prevalent in Asia. Second major radiotherapy program after Alpha DaRT.

11Cosmo Public Relations Corporation
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2020-09-23
Description

Strategic partnership and investment from Cosmo Healthcare to increase awareness and accessibility of bioscience innovations. Cosmo brings established network in Japanese healthcare communications and media.

heka.bio
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-10-15
Description

License and joint venture agreement for clinical development and commercialization of regenerative and cell/gene therapy products in Japan. Focus on diabetes and autoimmune diseases. Part of HekaBio's strategy to bring cell therapies to Japanese market leveraging favorable regulatory environment.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global biopharma services organization providing CRO and commercialization services across clinical development and commercial launch. Comparable business model to HekaBio's clinical execution and commercialization functions but at global scale and without HekaBio's Japan-only regulatory focus.

2Alfresa Holdings
TypeOthers
Description

Japan's #1 pharmaceutical wholesaler (¥2.9T consolidated sales) and HekaBio's strategic commercialization partner since June 2025. Included as an adjacent ecosystem participant — also a strategic investor — rather than a direct competitor since the relationship is partnership-based.

TypeBroad incumbent
Description

Leading Japanese pharma company with strong oncology pipeline and global commercialization capabilities. Relevant as a benchmark Japanese pharma incumbent and as a representative acquirer/strategic-partner profile for in-licensing platforms like HekaBio.

4Sosei Group
TypeDirect peer
Description

Tokyo-listed biopharma company that in-licenses and develops therapeutic candidates for Japan and global markets, including the Heptares GPCR platform. Highly comparable in-licensing and development model focused on Japan-rooted commercialization, though Sosei has more proprietary IP and is publicly traded at meaningful scale.

5EPS Holdings
TypeDirect peer
Description

Japanese CRO and healthcare services group supporting drug development, clinical trials, and post-marketing surveillance across Asia. Operates a similar asset-light services model in Japan and offers SMO/CRO/sales-promotion capabilities comparable to HekaBio's clinical execution and commercialization functions.

6Suzuken
TypeBroad incumbent
Description

One of Japan's top pharmaceutical wholesale groups with national distribution infrastructure. Comparable to Alfresa and Medipal as a potential channel partner; relevant as a benchmark for Japanese pharma distribution economics that ultimately govern HekaBio's launch royalty potential.

7MEDIPAL Holdings
TypeBroad incumbent
Description

Japan's second-largest pharmaceutical wholesaler (after Alfresa), distributing pharma products and medical devices nationwide. Comparable to Alfresa (HekaBio's distribution partner) — relevant as adjacent channel partner and as a potential competing commercialization route for Japanese market access.

TypeDirect peer
Description

Tokyo-headquartered pharma services company providing CRO, CDMO, SMO, and consulting services across Japan and APAC. Closely comparable to HekaBio's Japan-focused biopharma development and commercialization platform model, though CMIC is significantly larger and more diversified across service lines.

TypeDirect peer
Description

UK- and Asia-focused in-licensing and development platform (subsidiary of Sino Biopharmaceutical) that acquires and develops late-stage pharma assets. Similar asset-light in-licensing model with focus on bridging Western/Asian assets, though InvoX is better capitalized and operates at later asset stages.

TypeBroad incumbent
Description

Major Japanese-headquartered global pharma company with significant oncology and specialty therapeutics franchises. Comparable as a Japanese pharma incumbent that competes for licensed assets and that any large pharma acquirer of HekaBio would likely resemble.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

HekaBio

Biopharmaceutical and MedTech Licensing & Commercializationheka.bio

HekaBio is a Tokyo-based asset-light biopharma and MedTech platform that in-licenses early, de-risked healthcare innovations from overseas and commercializes them in Japan and APAC. It serves Japanese patients with cancer, autoimmune, CNS, and ophthalmic diseases, and overseas innovators seeking Japan/APAC market access.

What HekaBio does

HekaBio K.K. is a privately held Tokyo-based healthcare platform founded in 2016 that operates an asset-light in-licensing, development, and commercialization model for world-leading biopharma and MedTech assets in Japan and the broader APAC region. The company addresses the well-documented drug and device lag between Japan and Western markets by acquiring rights to de-risked, early-stage assets from overseas innovators and shepherding them through PMDA regulatory pathways, clinical trials, reimbursement negotiations, and commercial launch. HekaBio's portfolio spans approximately 50 programs across oncology, autoimmune and inflammatory diseases, CNS and neurodegenerative disorders, ophthalmology, and regenerative medicine, with its flagship Alpha DaRT alpha-particle radiation therapy system having received Shonin marketing approval from Japan's Ministry of Health, Labour and Welfare in February 2025 for unresectable locally advanced or recurrent head and neck cancer, marking the first regulatory approval for the platform outside Israel.

The company's revenue model is based on licensing milestones and royalties from commercialization of in-licensed products, supplemented by strategic investments from corporate partners. HekaBio holds Japanese regulatory permits for Class I medical device manufacturing/sales and highly managed medical device sales/rental, enabling it to directly commercialize approved products. Its go-to-market relies on channel partnerships, most notably with Alfresa Holdings (Japan's largest pharmaceutical wholesaler at 2.9 trillion yen consolidated sales) for nationwide distribution, and direct relationships with leading clinical centers including the National Cancer Center Hospital, Tohoku University Hospital, and the Institute of Science Tokyo for trial execution and clinical adoption. Core products include the Alpha DaRT System (intratumoral radium-224 alpha-particle therapy), Precision-GI endoscopic biopsy device (from Limaca Medical), BetaCurve ophthalmic radiation therapy (from SalutarisMD), troculeucel NK cell therapy (from NKGen Biotech), SP163M neuropathy peptide (from Serpin Pharma), and the K-EXP biomarker platform (from KIFFIK Biomedical).

HekaBio is led by co-founders Rob Claar (CEO) and Ben Pratt (COO), who leverage prior experience from Junicon K.K. (healthcare market research) and Vorpal Technologies K.K. (pharmaceutical and medical device CRO). The advisory and board bench includes former Japan presidents of AbbVie, Merck KGaA, and Pfizer, former Salesforce/Yext CFO Steven Cakebread, and international M&A attorney Stephen Chelberg of Squire Patton Boggs. The company is currently transitioning from a development-stage platform to commercial-stage operations following Alpha DaRT approval.

HekaBio firmographics

Firmographics
Name
HekaBio
Legal name
HekaBio K.K.
Website
https://heka.bio
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
HekaBio is a Tokyo-based asset-light biopharma and MedTech platform that in-licenses early, de-risked healthcare innovations from overseas and commercializes them in Japan and APAC. It serves Japanese patients with cancer, autoimmune, CNS, and ophthalmic diseases, and overseas innovators seeking Japan/APAC market access.
Ownership category
akta.pro rank

HekaBio industry classification

Industry
Product category
Biopharmaceutical and MedTech Licensing & Commercialization
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)
SIC
Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences

Keywords

  • Biopharma licensing platform
  • Medical device commercialization
  • Pharmaceutical market access
  • Radiation therapy oncology
  • Regulatory affairs Japan

Where HekaBio is headquartered

Location

Headquarters

HQ city
Tokyo
HQ country
Japan
HQ region
Asia

Offices1 record

Markets served

HekaBio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. Licensing and Commercialization: HekaBio generates revenue through licensing agreements with overseas biotech/MedTech companies for Japanese market rights. They earn milestone payments during development phases and royalties upon commercialization. They also receive strategic investments from partners.
  2. Strategic Investments: The company raises capital through private funding rounds from corporate investors and financial partners to fund portfolio expansion and operations.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

HekaBio product offering

Product offering

Core offering

HekaBio K.K. is a biopharma and MedTech in-licensing and commercialization platform that brings world-leading healthcare innovations to Japan and the Asia-Pacific region. The company identifies, de-risks, clinically develops, secures regulatory approval (PMDA), and commercially launches overseas assets across oncology (including the approved Alpha DaRT alpha-radiation therapy), ophthalmology (BetaCurve), regenerative medicine (troculeucel NK cell therapy), and diagnostics (Precision-GI biopsy device), with revenue generated primarily through licensing milestones and royalties from partners such as Alpha Tau Medical, Limaca Medical, SalutarisMD, NKGen Biotech, and Serpin Pharma.

Product overview

HekaBio is an asset-light emerging commercial-stage biopharma and MedTech platform that in-licenses, develops, and commercializes world-leading healthcare innovations in Japan and the Asia-Pacific region. The company operates as a portfolio of partnered products rather than a single unified product. Its core offerings include the Alpha DaRT System (alpha-particle radiation cancer therapy) as its primary commercial product, supplemented by partnership-based products including Precision-GI (endoscopic biopsy device), K-EXP Platform (interstitial fluid diagnostics), BetaCurve (ophthalmic radiation therapy), troculeucel (NK cell therapy), SP163M (neuropathy treatment), and the Terrapeutics drug discovery platform. HekaBio focuses on oncology, CNS/neurodegenerative diseases, and autoimmune/inflammatory disorders, providing clinical development, regulatory navigation, and commercialization support through its network of pharma, MedTech, and hospital partners.

Differentiator

Problem solved

Functional benefit

Products and services

  • Alpha DaRT System Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is an alpha-particle cancer treatment that delivers intratumoral radium-224 sources to destroy solid tumors while sparing healthy tissue. HekaBio's primary commercial product, licensed from Alpha Tau Medical, received Shonin marketing approval in Japan for unresectable locally advanced or recurrent head and neck cancer.
  • Precision-GI Endoscopic Biopsy Device Precision-GI is an automated motorized endoscopic ultrasound (EUS) biopsy device developed by Limaca Medical for improved tissue sampling in gastrointestinal cancer diagnosis, particularly pancreatic cancer. HekaBio holds Japanese commercialization rights and is preparing the device for the Japan market following its FDA 510(k) clearance.
  • BetaCurve BetaCurve is an ophthalmic device developed by SalutarisMD that incorporates Strontium-90 for controlled delivery of episcleral radiation to treat Polypoidal Choroidal Vasculopathy (PCV), a subset of neovascular Age-related Macular Degeneration with high prevalence in Asia. HekaBio holds Japan commercialization rights.
  • troculeucel (Autologous NK Cell Therapy) Troculeucel is an autologous NK cell therapy developed by NKGen Biotech intended for treating neurodegenerative diseases including Alzheimer's disease and Parkinson's disease. HekaBio is partnering to bring troculeucel to Japan under Japan's regenerative medicine regulatory framework.
  • K-EXP Interstitial Fluid Molecular Measurement Platform The K-EXP platform, developed by KIFFIK Biomedical, performs interstitial fluid (ISF) molecular measurement enabling biomarker detection across oncology, cardiology, neurology, and dermatology. HekaBio is leading the platform's expansion across Japan and the Asia-Pacific region.
  • SP163M Peptide Drug SP163M is a peptide drug developed by Serpin Pharma for prevention of chemotherapy-induced peripheral neuropathy (CIPN). It protects nerves from neurotoxic chemotherapy drugs, facilitates nerve repair, and alleviates pain. HekaBio holds the commercialization lead in Japan, Korea, Taiwan, Australia, ASEAN, the Middle East, and North Africa.

Quantifiable outcome

  • Portfolio of nearly 50 programs under management
  • +1 more outcomes

Companies that use HekaBio

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

HekaBio technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

HekaBio partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core and minor.

  • KIFFIK BiomedicalcoreStrategic or Co-development Partner · 24 March 2026Strategic alliance to expand K-EXP interstitial fluid (ISF) molecular measurement platform across Japan and APAC. HekaBio will support regulatory strategy in Japan, serve as local strategic advisor, and assist in establishing clinical and commercial partnerships in Japan and Korea. Platform enables biomarker detection across oncology, cardiology, neurology, and dermatology.
  • Alpha Tau Medical Ltd.coreStrategic or Co-development Partner · 24 February 2026Long-standing partnership to develop and commercialize Alpha DaRT (Diffusing Alpha Radiation Therapy) for solid tumors in Japan. Alpha Tau developed the technology and obtained Japanese regulatory approval (Shonin) through HekaBio's support. HekaBio preparing commercial launch and post-marketing surveillance. Japan is first country outside Israel to approve this innovative alpha-particle cancer therapy.
  • TOWER Capital GroupminorStrategic or Co-development Partner · 2 October 2025Strategic partnership to expand generational health access in Japan. Partnership focuses on delivering innovative healthcare solutions across generations through global investment platform capabilities.
  • Indonesia Inovasi SehatminorStrategic or Co-development Partner · 1 October 2025Strategic agreement to promote advanced medical technology adoption in Indonesia. Partnership aims to improve patient outcomes by delivering innovative solutions to healthcare providers, reflecting shared mission across borders.
  • NKGen BiotechcoreStrategic or Co-development Partner · 21 July 2025Strategic partnership to bring novel autologous NK cell therapy (troculeucel) to Japan for neurodegenerative diseases including Alzheimer's and Parkinson's. Partnership aims to accelerate regulatory, manufacturing, and commercialization processes under Japan's regenerative medicine regulations.
  • Alfresa Holdings CorporationcoreChannel Partner/ Reseller/ Distributor · 16 June 2025Strategic commercialization partnership with Japan's #1 pharmaceutical wholesale company (2.9 trillion yen consolidated sales). Alfresa will support distribution and commercialization of innovative pharmaceutical products. HekaBio also received capital investment from Alfresa as part of this partnership to accelerate market entry.
  • Serpin PharmaminorStrategic or Co-development Partner · 9 July 2024Partnership for SP163M peptide drug development to prevent chemotherapy-induced peripheral neuropathy (CIPN). HekaBio will lead commercialization in Japan, Korea, Taiwan, Australia, ASEAN, Middle East, and North Africa. Includes strategic investment in Serpin Pharma.
  • Terrapeutics Pharma Ltd.minorStrategic or Co-development Partner · 19 June 2024Partnership to introduce Terrapeutics' innovative drug discovery platform leveraging soil bacteria-derived molecules to Japanese pharma. HekaBio CEO Rob Claar joins Terrapeutics' Advisory Board. Platform enables rapid identification of natural inhibitors for challenging drug targets.
  • Limaca Medical Ltd.coreStrategic or Co-development Partner · 17 May 2022Partnership for Precision-GI endoscopic biopsy device for Japanese market. HekaBio supporting regulatory approval from PMDA, sales preparation, physician training, and domestic logistics. Device received FDA 510(k) clearance and CMS TPT payment approval in US, with HekaBio pursuing Japanese commercialization.
  • SalutarisMDcoreStrategic or Co-development Partner · 9 July 2021Licensing and commercialization agreement for BetaCurve device - Sr90 beta radiation delivery system for Polypoidal Choroidal Vasculopathy (PCV) treatment, a subset of wet age-related macular degeneration prevalent in Asia. Second major radiotherapy program after Alpha DaRT.
  • Cosmo Public Relations CorporationminorGTM or Marketing Partner · 23 September 2020Strategic partnership and investment from Cosmo Healthcare to increase awareness and accessibility of bioscience innovations. Cosmo brings established network in Japanese healthcare communications and media.
  • Orgenesis Inc.coreStrategic or Co-development Partner · 15 October 2018License and joint venture agreement for clinical development and commercialization of regenerative and cell/gene therapy products in Japan. Focus on diabetes and autoimmune diseases. Part of HekaBio's strategy to bring cell therapies to Japanese market leveraging favorable regulatory environment.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

HekaBio competitors and assessment

Company assessment

Broad incumbents

  • Syneos Health: Global biopharma services organization providing CRO and commercialization services across clinical development and commercial launch. Comparable business model to HekaBio's clinical execution and commercialization functions but at global scale and without HekaBio's Japan-only regulatory focus.
  • Daiichi Sankyo: Leading Japanese pharma company with strong oncology pipeline and global commercialization capabilities. Relevant as a benchmark Japanese pharma incumbent and as a representative acquirer/strategic-partner profile for in-licensing platforms like HekaBio.
  • Suzuken: One of Japan's top pharmaceutical wholesale groups with national distribution infrastructure. Comparable to Alfresa and Medipal as a potential channel partner; relevant as a benchmark for Japanese pharma distribution economics that ultimately govern HekaBio's launch royalty potential.
  • MEDIPAL Holdings: Japan's second-largest pharmaceutical wholesaler (after Alfresa), distributing pharma products and medical devices nationwide. Comparable to Alfresa (HekaBio's distribution partner) — relevant as adjacent channel partner and as a potential competing commercialization route for Japanese market access.
  • Astellas Pharma: Major Japanese-headquartered global pharma company with significant oncology and specialty therapeutics franchises. Comparable as a Japanese pharma incumbent that competes for licensed assets and that any large pharma acquirer of HekaBio would likely resemble.

Others

  • Alfresa Holdings: Japan's #1 pharmaceutical wholesaler (¥2.9T consolidated sales) and HekaBio's strategic commercialization partner since June 2025. Included as an adjacent ecosystem participant — also a strategic investor — rather than a direct competitor since the relationship is partnership-based.

Direct peers

  • Sosei Group: Tokyo-listed biopharma company that in-licenses and develops therapeutic candidates for Japan and global markets, including the Heptares GPCR platform. Highly comparable in-licensing and development model focused on Japan-rooted commercialization, though Sosei has more proprietary IP and is publicly traded at meaningful scale.
  • EPS Holdings: Japanese CRO and healthcare services group supporting drug development, clinical trials, and post-marketing surveillance across Asia. Operates a similar asset-light services model in Japan and offers SMO/CRO/sales-promotion capabilities comparable to HekaBio's clinical execution and commercialization functions.
  • CMIC Group: Tokyo-headquartered pharma services company providing CRO, CDMO, SMO, and consulting services across Japan and APAC. Closely comparable to HekaBio's Japan-focused biopharma development and commercialization platform model, though CMIC is significantly larger and more diversified across service lines.
  • InvoX Pharma: UK- and Asia-focused in-licensing and development platform (subsidiary of Sino Biopharmaceutical) that acquires and develops late-stage pharma assets. Similar asset-light in-licensing model with focus on bridging Western/Asian assets, though InvoX is better capitalized and operates at later asset stages.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

HekaBio social profiles

Digital presence

HekaBio compliance and trust

Trust signal

Compliance3 records

HekaBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HekaBio leadership team

Management profile

Number of profiles

Profiles9 records

HekaBio subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

HekaBio funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HekaBio M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HekaBio

What does HekaBio do?

HekaBio K.K. is a biopharma and MedTech in-licensing and commercialization platform that brings world-leading healthcare innovations to Japan and the Asia-Pacific region. The company identifies, de-risks, clinically develops, secures regulatory approval (PMDA), and commercially launches overseas assets across oncology (including the approved Alpha DaRT alpha-radiation therapy), ophthalmology (BetaCurve), regenerative medicine (troculeucel NK cell therapy), and diagnostics (Precision-GI biopsy device), with revenue generated primarily through licensing milestones and royalties from partners such as Alpha Tau Medical, Limaca Medical, SalutarisMD, NKGen Biotech, and Serpin Pharma.

Is HekaBio a public or private company?

HekaBio is a private company. It is classified as venture growth investor backed and is currently operating.

When was HekaBio founded?

HekaBio was founded in 2016. It employs 11 to 50 people.

Where is HekaBio based?

HekaBio is headquartered in Tokyo, Japan, in the Asia region.

How does HekaBio make money?

Two revenue lines are on record. Licensing and Commercialization is the primary driver. The others are strategic Investments.

Who are HekaBio's main competitors?

Broad incumbents on record are Syneos Health, Daiichi Sankyo, Suzuken, MEDIPAL Holdings and Astellas Pharma. Alfresa Holdings is listed as an others. Direct peers are Sosei Group, EPS Holdings, CMIC Group and InvoX Pharma.

Does HekaBio have an API?

No public API is recorded for HekaBio.

What industry is HekaBio in?

HekaBio's product category is Biopharmaceutical and MedTech Licensing & Commercialization. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support. Its NAICS code is 541714 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PharmiWeb.comKIFFIK Biomedical and HekaBio Announce Strategic Alliance to Expand ISF-Based Molecular Access Across Asia-PacificKIFFIK Biomedical announced a strategic alliance with HekaBio K.K. to expand its K-EXP™ interstitial fluid (ISF) molecular measurement platform across Japan and the broader Asia-Pacific region. Under the agreement, HekaBio will support KIFFIK's regulatory strategy in Japan, serve as a local strategic advisor, and assist in establishing clinical and commercial partnerships in Japan and Korea. The K-EXP platform enables direct access to interstitial fluid for biomarker detection across oncology, cardiology, neurology, and dermatology applications.Stock TitanAlpha Tau wins Japan Shonin approval for Alpha DaRTAlpha Tau Medical Ltd. received Shonin marketing approval from Japan’s Ministry of Health, Labour and Welfare for its Alpha DaRT alpha-radiation cancer therapy to treat unresectable locally advanced or locally recurrent head and neck cancer, marking the first regulatory approval for the platform outside Israel. The approval requires a post-market surveillance study enrolling 66 patients across five leading Japanese clinical centers, with commercial partner HekaBio preparing the launch. The approval represents a rare case of Japan authorizing a foreign-originated new category medical device ahead of the US and Europe, positioning Alpha Tau to enter Japan’s third-largest global healthcare market.MorningstarHekaBio and Alpha Tau Medical Obtain Approval in Japan for Solid Tumor Treatment Alpha DaRTHekaBio K.K. and Alpha Tau Medical Ltd. announced that their Alpha DaRT (Diffusing Alpha Radiation Therapy) device has received regulatory approval (Shonin) in Japan for treating unresectable locally advanced or recurrent head and neck cancer. Japan becomes the first country outside of Israel to approve this innovative alpha-particle cancer therapy, which uses intratumorally placed radium-224 sources to destroy tumor cells while minimizing damage to surrounding healthy tissue. HekaBio will prepare for commercial launch in Japan while conducting post-marketing surveillance studies and discussing potential reimbursement with Japan's Ministry of Health, Labour and Welfare.Stock TitanNK Cell Therapy Troculeucel Fast-Tracked for Alzheimer's Treatment in JapanNKGen Biotech and HekaBio announced a strategic partnership to accelerate the development of NKGen's autologous NK cell therapy troculeucel in Japan. HekaBio will lead clinical trials and regulatory activities, aiming for first dosing in Japanese patients within 12 months. The therapy targets neurodegenerative diseases like Alzheimer's and Parkinson's.PR NewswireRevolutionizing Cardiac MRI Examinations: Vista.ai and HekaBio Announce Japan PartnershipVista.ai and HekaBio K.K. have signed a strategic partnership agreement for HekaBio to market Vista.ai's FDA-cleared One Click™ AI-assisted cardiac MRI software in Japan, with HekaBio making an investment in Vista.ai and committing to secure product registration through Japan's Ministry of Health, Labour and Welfare. Japan has the world's highest MRI equipment per capita but currently low adoption of cardiac MRI due to the complexity and specialized expertise required for the procedure. Vista.ai CEO Juan Santos stated the partnership aims to increase patient access to cardiac MRI examinations in Japan, leveraging HekaBio's market expertise as the ideal commercialization partner.PR NewswireAlpha Tau Announces Completion of Enrollment of Japanese Pivotal Clinical Trial in Recurrent Head & Neck CancerAlpha Tau Medical announced the completion of enrollment in its Japanese pivotal clinical trial evaluating the Alpha DaRT alpha-radiation therapy for recurrent head and neck cancer, conducted by its partner HekaBio K.K. HekaBio reported that preliminary results are highly encouraging and will prepare a submission seeking marketing approval via Japan's shonin pathway. The company, which already holds its first marketing authorization in Israel, is also planning to initiate a pivotal trial in the United States in 2022 as part of its global expansion strategy.PR NewswireCosmo PR and HekaBio Announce Strategic Partnership and Investment in HekaBioHekaBio K.K. and Cosmo Public Relations Corporation announced a strategic partnership and undisclosed investment, with Cosmo acquiring a stake in the Japanese bioscience venture. The partnership aims to leverage Cosmo Healthcare's established network to advance HekaBio's portfolio of around 50 MedTech, pharma, and regenerative medicine programs targeting unmet patient needs in Japan. HekaBio, which operates as an in-licensing bio venture and CRO, gains expanded market reach while Cosmobroadens its healthcare innovation communications capabilities in the Japanese market.CTechIsraeli Oncology Company Alpha Tau is Raising FundsIsraeli oncology company Alpha Tau is in the final stages of raising an investment of several tens of millions of dollars, expected to close by month's end. The company has raised $25 million to date and announced its Alpha DaRT technology received approval from the Massachusetts Radiation Control Program, enabling US clinical trials. It also plans a US production facility and a joint venture with HekaBio K.K. in Japan.